Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wies R Vallentgoed

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancers|December 7, 2018
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung AdenocarcinomasYa Gao, Wies R Vallentgoed, Pim J French
European Journal of Cancer (Oxford, England : 1990)|September 24, 2022
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic reviewC Mircea S Tesileanu, Wies R Vallentgoed, Pim J French, et al.
Iscience|January 2, 2023
Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling dataLevi van Hijfte, Marjolein Geurts, Wies R Vallentgoed, et al.
Nature Communications|January 29, 2025
Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytomaLevi van Hijfte, Marjolein Geurts, Iris de Heer, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology Advances|November 29, 2023
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohortKarin A van Garderen, Wies R Vallentgoed, Anna Lavrova, et al.
Cell Reports. Medicine|March 18, 2026
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomasYouri Hoogstrate, Santoesha A Ghisai, Levi van Hijfte, et al.
Nature Cancer|August 19, 2025
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cyclingWies R Vallentgoed, Youri Hoogstrate, Karin A van Garderen, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancers|December 7, 2018
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung AdenocarcinomasYa Gao, Wies R Vallentgoed, Pim J French
European Journal of Cancer (Oxford, England : 1990)|September 24, 2022
Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic reviewC Mircea S Tesileanu, Wies R Vallentgoed, Pim J French, et al.
Iscience|January 2, 2023
Alternative normalization and analysis pipeline to address systematic bias in NanoString GeoMx Digital Spatial Profiling dataLevi van Hijfte, Marjolein Geurts, Wies R Vallentgoed, et al.
Nature Communications|January 29, 2025
Gemistocytic tumor cells programmed for glial scarring characterize T cell confinement in IDH-mutant astrocytomaLevi van Hijfte, Marjolein Geurts, Iris de Heer, et al.
Acta Neuropathologica|October 9, 2024
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytomaSantoesha A Ghisai, Levi van Hijfte, Wies R Vallentgoed, et al.
Neuro-Oncology Advances|November 29, 2023
Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohortKarin A van Garderen, Wies R Vallentgoed, Anna Lavrova, et al.
Cell Reports. Medicine|March 18, 2026
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomasYouri Hoogstrate, Santoesha A Ghisai, Levi van Hijfte, et al.
Nature Cancer|August 19, 2025
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cyclingWies R Vallentgoed, Youri Hoogstrate, Karin A van Garderen, et al.
Acta Neuropathologica|March 19, 2021
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutationsC Mircea S Tesileanu, Wies R Vallentgoed, Marc Sanson, et al.
Pageof 2